The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action

Franca Riganti, Marina Sironi, Marcela Kankova, Maurizio D'Incalci, Federico Spreafico, Alberto Mantovani, Annunciata Vecchi

Research output: Contribution to journalArticle

Abstract

The present study was designed to characterize in mice the effects on the immune system of the antineoplastic agent FCE 24157, a benzoic acid mustard derivative of distamycin A with specificity for AT-rich base pair sequences of β-DNA. At antitumorally therapeutic doses, single injections of FCE 24517 caused profound leukopenia and a decrease of spleen cell numbers. However, primary and secondary antibody production to the T-dependent antigen sheep red blood cells were markedly increased by FCE 24517 given before or together with antigen. Antibody production to the T-independent antigen type III pneumococcal polysaccharide was not appreciably affected by FCE 24517. The delayed type hypersensitivity response to sheep erythrocytes was only marginally decreased, whereas proliferation of spleen cells to mitogens was markedly depressed. The ability of natural killer cells and marcophages to mediate cytotoxicity was not affected by FCE 24517 treatment. The ability of carrier-primed cells from drug-treated mice to cooperate for anti-trinitrophenyl antibody production increased twofold over that of vehicle-injected controls, suggesting an increase in T-helper cell activity. Serum cytokine levels were studied in mice injected with bacterial lipopolysaccharide used as a model stimulus. Peak levels of TNF and IL-6 were not modified by FCE 24517, but at later times higher amounts of cytokines were found in drug-treated mice compared with the control, suggesting a longer exposure of immunocompetent cells to these factors. Two compounds (FCE 24561 and CC-1065), also capable of binding AT-rich sequences in the minor groove of β-DNA and containing an alkylating moiety, had immunomodulatory activity similar to FCE 24517 in increasing primary anti-sheep erythrocytes response. It is concluded that FCE 24517 exhibits a unique interaction with the immune system, markedly different from that of alkylating agents and may be representative of a novel group of antiproliferative-immunomodulating agents.

Original languageEnglish
Pages (from-to)239-251
Number of pages13
JournalInternational Journal of Immunopharmacology
Volume14
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Antineoplastic Agents
Immunity
Antibody Formation
Sheep
Erythrocytes
CC 1065
Immune System
Spleen
AT Rich Sequence
T Independent Antigens
Cytokines
Mustard Plant
Benzoic Acid
Alkylating Agents
Viral Tumor Antigens
Leukopenia
Delayed Hypersensitivity
Helper-Inducer T-Lymphocytes
tallimustine
Mitogens

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action. / Riganti, Franca; Sironi, Marina; Kankova, Marcela; D'Incalci, Maurizio; Spreafico, Federico; Mantovani, Alberto; Vecchi, Annunciata.

In: International Journal of Immunopharmacology, Vol. 14, No. 2, 1992, p. 239-251.

Research output: Contribution to journalArticle

@article{64205136ad72470d8a65b5c268c997d0,
title = "The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action",
abstract = "The present study was designed to characterize in mice the effects on the immune system of the antineoplastic agent FCE 24157, a benzoic acid mustard derivative of distamycin A with specificity for AT-rich base pair sequences of β-DNA. At antitumorally therapeutic doses, single injections of FCE 24517 caused profound leukopenia and a decrease of spleen cell numbers. However, primary and secondary antibody production to the T-dependent antigen sheep red blood cells were markedly increased by FCE 24517 given before or together with antigen. Antibody production to the T-independent antigen type III pneumococcal polysaccharide was not appreciably affected by FCE 24517. The delayed type hypersensitivity response to sheep erythrocytes was only marginally decreased, whereas proliferation of spleen cells to mitogens was markedly depressed. The ability of natural killer cells and marcophages to mediate cytotoxicity was not affected by FCE 24517 treatment. The ability of carrier-primed cells from drug-treated mice to cooperate for anti-trinitrophenyl antibody production increased twofold over that of vehicle-injected controls, suggesting an increase in T-helper cell activity. Serum cytokine levels were studied in mice injected with bacterial lipopolysaccharide used as a model stimulus. Peak levels of TNF and IL-6 were not modified by FCE 24517, but at later times higher amounts of cytokines were found in drug-treated mice compared with the control, suggesting a longer exposure of immunocompetent cells to these factors. Two compounds (FCE 24561 and CC-1065), also capable of binding AT-rich sequences in the minor groove of β-DNA and containing an alkylating moiety, had immunomodulatory activity similar to FCE 24517 in increasing primary anti-sheep erythrocytes response. It is concluded that FCE 24517 exhibits a unique interaction with the immune system, markedly different from that of alkylating agents and may be representative of a novel group of antiproliferative-immunomodulating agents.",
author = "Franca Riganti and Marina Sironi and Marcela Kankova and Maurizio D'Incalci and Federico Spreafico and Alberto Mantovani and Annunciata Vecchi",
year = "1992",
doi = "10.1016/0192-0561(92)90036-K",
language = "English",
volume = "14",
pages = "239--251",
journal = "International Journal of Immunopharmacology",
issn = "0192-0561",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action

AU - Riganti, Franca

AU - Sironi, Marina

AU - Kankova, Marcela

AU - D'Incalci, Maurizio

AU - Spreafico, Federico

AU - Mantovani, Alberto

AU - Vecchi, Annunciata

PY - 1992

Y1 - 1992

N2 - The present study was designed to characterize in mice the effects on the immune system of the antineoplastic agent FCE 24157, a benzoic acid mustard derivative of distamycin A with specificity for AT-rich base pair sequences of β-DNA. At antitumorally therapeutic doses, single injections of FCE 24517 caused profound leukopenia and a decrease of spleen cell numbers. However, primary and secondary antibody production to the T-dependent antigen sheep red blood cells were markedly increased by FCE 24517 given before or together with antigen. Antibody production to the T-independent antigen type III pneumococcal polysaccharide was not appreciably affected by FCE 24517. The delayed type hypersensitivity response to sheep erythrocytes was only marginally decreased, whereas proliferation of spleen cells to mitogens was markedly depressed. The ability of natural killer cells and marcophages to mediate cytotoxicity was not affected by FCE 24517 treatment. The ability of carrier-primed cells from drug-treated mice to cooperate for anti-trinitrophenyl antibody production increased twofold over that of vehicle-injected controls, suggesting an increase in T-helper cell activity. Serum cytokine levels were studied in mice injected with bacterial lipopolysaccharide used as a model stimulus. Peak levels of TNF and IL-6 were not modified by FCE 24517, but at later times higher amounts of cytokines were found in drug-treated mice compared with the control, suggesting a longer exposure of immunocompetent cells to these factors. Two compounds (FCE 24561 and CC-1065), also capable of binding AT-rich sequences in the minor groove of β-DNA and containing an alkylating moiety, had immunomodulatory activity similar to FCE 24517 in increasing primary anti-sheep erythrocytes response. It is concluded that FCE 24517 exhibits a unique interaction with the immune system, markedly different from that of alkylating agents and may be representative of a novel group of antiproliferative-immunomodulating agents.

AB - The present study was designed to characterize in mice the effects on the immune system of the antineoplastic agent FCE 24157, a benzoic acid mustard derivative of distamycin A with specificity for AT-rich base pair sequences of β-DNA. At antitumorally therapeutic doses, single injections of FCE 24517 caused profound leukopenia and a decrease of spleen cell numbers. However, primary and secondary antibody production to the T-dependent antigen sheep red blood cells were markedly increased by FCE 24517 given before or together with antigen. Antibody production to the T-independent antigen type III pneumococcal polysaccharide was not appreciably affected by FCE 24517. The delayed type hypersensitivity response to sheep erythrocytes was only marginally decreased, whereas proliferation of spleen cells to mitogens was markedly depressed. The ability of natural killer cells and marcophages to mediate cytotoxicity was not affected by FCE 24517 treatment. The ability of carrier-primed cells from drug-treated mice to cooperate for anti-trinitrophenyl antibody production increased twofold over that of vehicle-injected controls, suggesting an increase in T-helper cell activity. Serum cytokine levels were studied in mice injected with bacterial lipopolysaccharide used as a model stimulus. Peak levels of TNF and IL-6 were not modified by FCE 24517, but at later times higher amounts of cytokines were found in drug-treated mice compared with the control, suggesting a longer exposure of immunocompetent cells to these factors. Two compounds (FCE 24561 and CC-1065), also capable of binding AT-rich sequences in the minor groove of β-DNA and containing an alkylating moiety, had immunomodulatory activity similar to FCE 24517 in increasing primary anti-sheep erythrocytes response. It is concluded that FCE 24517 exhibits a unique interaction with the immune system, markedly different from that of alkylating agents and may be representative of a novel group of antiproliferative-immunomodulating agents.

UR - http://www.scopus.com/inward/record.url?scp=0026532645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026532645&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(92)90036-K

DO - 10.1016/0192-0561(92)90036-K

M3 - Article

C2 - 1624224

AN - SCOPUS:0026532645

VL - 14

SP - 239

EP - 251

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

SN - 0192-0561

IS - 2

ER -